Inclusion Criteria:
* Male aged 40-80 years old
* 7 ≤ IPSS score \<19
* The subject did not take α-blocker or anticholinergic agents in the last 8 weeks. The subject did not take 5α-reductase inhibitor or androgen suppression agents in the last 16 weeks (depending on medical history).
* The subject isn't diagnosed with cancer
* The subject is able to read and finish the information on the questionnaire.
* The subject must read and sign the informed consent form after the study has been fully explained.
Exclusion criteria:
* The subject has a history of epilepsy or convulsions, liver and kidney disease, cancer, endocrine disease, mental illness, alcohol or drug abuse, and other major organic diseases (depending on medical history).
* The lower urinary tract urination symptoms of the subject are not related to prostatic hypertrophy (depending on medical history).
* Residual urine volume \> 250 mL (depending on medical history)
* Subjects have had pelvic radiation therapy or pelvic surgery (including prostate or bladder surgery, but those who only have had a prostate slice can participate in the trial).
* Planned invasive procedures or examinations during the trial period, including prostate surgery, prostate biopsy, cystourethroscopy, pelvic surgery, exploratory laparotomy, or any treatment requiring the use of a urinary catheter.
* Subjects have taken sexual hormone preparations including LHRH agonists, anti-androgens, feminine, or Penta-reductase inhibitors (Proscar and Avodart) 16 weeks prior to the trial.
* Subjects have participated in other clinical trials 12 weeks prior to the trial.
* History or detection of prostate cancer (e.g., positive tissue biopsy or ultrasound findings, or suspected abnormalities on digital rectal examination \[DRE\]). However, subjects with suspected abnormalities on ultrasound or DRE may participate if they had a negative biopsy within the past 6 months and demonstrate stable Prostate-Specific Antigen (PSA) levels (based on medical history).
